DelveInsight’s latest publication, “Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast – 2032,” presents an in-depth exploration of the Non-Alcoholic Fatty Liver Disease landscape. This report offers valuable insights into epidemiological patterns, current treatment options, and evolving market dynamics across key regions, including the United States, the five major European countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Learn More About Market Landscape, Drug Uptake, and Epidemiology Trends:
Key Highlights from the Non-Alcoholic Fatty Liver Disease Market Report:
The market for Non-Alcoholic Fatty Liver Disease is anticipated to demonstrate substantial growth with a strong Compound Annual Growth Rate (CAGR) forecasted throughout the 2019–2032 period.
- December 2024: Galectin Therapeutics announced findings from the NAVIGATE global trial assessing belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
- October 2024: PharmaIN Corporation released interim results from its Phase I clinical trial evaluating PHIN-214, aimed at preventing and treating decompensated cirrhosis.
The current Non-Alcoholic Steatohepatitis (NASH) treatment pipeline includes a variety of emerging drug classes such as:
- Farnesoid X Receptor (FXR) agonists
- Fibroblast Growth Factor 21 (FGF21) and Fibroblast Growth Factor 19 (FGF19) analogs
- Glucagon-Like Peptide-1 (GLP-1) receptor agonists
- Peroxisome Proliferator-Activated Receptor (PPAR) modulators
- Thyroid Hormone Receptor Beta (THR-β) agonists
According to the American Liver Foundation, Non-Alcoholic Fatty Liver Disease is the most widespread chronic liver condition in the United States, affecting nearly 25% of the adult population, with approximately 20% of those cases advancing to Non-Alcoholic Steatohepatitis (NASH).
Further evidence from the Bagnacavallo Study (Foschi et al., 2019) in Northern Italy showed a Non-Alcoholic Fatty Liver Disease prevalence of 46% in individuals with abnormal liver enzymes, compared to 22% in those without.
Leading Companies in the Non-Alcoholic Fatty Liver Disease Market:
Key players driving innovation and market expansion include:
- Inventiva Pharma
- Eli Lilly and Company
- Madrigal Pharmaceuticals
- Intercept Pharmaceuticals
- 89bio
- Novo Nordisk A/S
- NeuroBo Pharmaceuticals
- J2H Biotech
- Haisco Pharmaceutical
- Altimmune
- GlaxoSmithKline
- Axcella Health
- AstraZeneca
- Gannex Pharma
- Dexa Medica
- Boehringer Ingelheim
- Can-Fite BioPharma
- Rivus Pharmaceuticals
- Regeneron Pharmaceuticals
- MediciNova
Pipeline of Notable Therapies Under Development:
Highlighted drug candidates in the pipeline include:
- Lanifibranor (Inventiva Pharma)
- Tirzepatide (Eli Lilly and Company)
- MGL-3196 (Resmetirom) (Madrigal Pharmaceuticals)
- Obeticholic acid (Intercept Pharmaceuticals)
- Pegozafermin (89bio)
- Semaglutide (Novo Nordisk A/S)
- DA-1241 (NeuroBo Pharmaceuticals)
- NNC0194 0499 (Novo Nordisk A/S)
- J2H-1702 (J2H Biotech)
- HSK31679 (Haisco Pharmaceutical)
- Pemvidutide (Altimmune)
- GSK4532990 (GlaxoSmithKline)
- AXA1125 (Axcella Health)
- AZD9550 (AstraZeneca)
- ASC41 2mg (Gannex Pharma)
- Proliverenol (Dexa Medica)
- Survodutide (Boehringer Ingelheim)
- Namodenoson (Can-Fite BioPharma)
- HU6 (Rivus Pharmaceuticals)
- ALN-HSD (Regeneron Pharmaceuticals)
- MN-001 (MediciNova)
These therapeutic candidates are expected to transform the treatment landscape for Non-Alcoholic Fatty Liver Disease, particularly Non-Alcoholic Steatohepatitis, as they progress through clinical trials and move toward potential approval.
Overview of Non-Alcoholic Fatty Liver Disease:
Non-Alcoholic Fatty Liver Disease is a progressive liver condition characterized by fat accumulation in the liver not attributed to alcohol consumption. It ranges from simple steatosis to more serious conditions such as Non-Alcoholic Steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma (liver cancer).
Epidemiological Trends of Non-Alcoholic Fatty Liver Disease:
DelveInsight’s analysis tracks epidemiological developments from 2019 through 2032 across major global markets. It includes:
- Overall prevalence of Non-Alcoholic Fatty Liver Disease
- Prevalence rates segmented by disease severity
- Gender-specific incidence data
- Diagnosed populations of both acute and chronic forms
These projections are supported by expert analysis and large-scale observational studies, offering a clear picture of disease burden and emerging challenges.
Discover more about therapies set to grab major Non-Alcoholic Fatty Liver Disease market share @ Non-Alcoholic Fatty Liver Disease Treatment Market : https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market?utm_source=reportstoreutm_medium=promotionutm_campaign=akpr
Therapeutic Adoption Pipeline Dynamics:
The section on drug uptake evaluates how quickly new treatments are entering the market, their real-world effectiveness, and predicted adoption rates. It also highlights the top-performing therapies based on patient response and commercial success.
In addition, detailed pipeline analytics provide a window into the status of ongoing research and development, collaboration deals, and other pivotal advancements in drug development.
Market Growth Drivers and Opportunities:
Strengths:
- Intensive RD activity in Non-Alcoholic Steatohepatitis therapeutics
- Multiple drugs in mid-to-late stage trials indicating a vibrant innovation ecosystem
Opportunities:
- The United States stands out as a high-potential growth region due to the significant prevalence of Non-Alcoholic Steatohepatitis and related liver disorders
Report Scope and Analytical Framework:
- Study Period: 2019–2032
- Geographic Focus: United States, Germany, France, Italy, Spain, United Kingdom, and Japan
- Market Intelligence Tools Used: SWOT Analysis, PESTLE Framework, Porter’s Five Forces, BCG Matrix
- Key Coverage: Leading pharmaceutical companies, pipeline therapies, reimbursement policies, and market access insights
To know more about Non-Alcoholic Fatty Liver Disease companies working in the treatment market, visit
Table of Contents (Key Sections):
- Introduction
- Executive Summary
- SWOT Analysis
- Patient Share Overview
- Market Overview
- Disease Background
- Epidemiology Analysis
- Country-specific Patient Insights
- Treatment Landscape
- Unmet Needs
- Emerging Therapies
- Market Forecast and Outlook
- Regional Market Analysis (2019–2032)
- Market Access Reimbursement
- Market Drivers
- Market Barriers
- Appendix
- Methodology
- About DelveInsight
- Disclaimer
Related Reports:
Non-Alcoholic Fatty Liver Disease Pipeline https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=reportstoreutm_medium=promotionutm_campaign=akpr
"Non-Alcoholic Fatty Liver Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-Alcoholic Fatty Liver Disease market. A detailed picture of the Non-Alcoholic Fatty Liver Disease pipeline landscape is provided, which includes the disease overview and Non-Alcoholic Fatty Liver Disease treatment guidelines.
Non-Alcoholic Fatty Liver Disease Epidemiology https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-epidemiology-forecast?utm_source=reportstoreutm_medium=promotionutm_campaign=akpr
DelveInsight's 'Non-Alcoholic Fatty Liver Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Non-Alcoholic Fatty Liver Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight:
Adult T-Cell Leukemia Market | Arthralgia Market | Atrial Flutter Market | Attention Deficit Hyperactivity Disorder Market | Bacterial Meningitis Market | Biopsy Devices Market | CART Pipeline | Chlamydia Infections Market | Chronic Neuropathic Pain Market | Convulsive Seizures Market | Coronary Angioplasty Market | Diabetic Gastroparesis Market | Diabetic Nephropathy Market | Electrophysiology Devices Market | Ewing Sarcoma Market | Fabry Disease Market | Gene Therapy In CNS Disorder Market | Glioblastoma Multiforme Market | Graves Disease Market | Hay Fever Conjunctivitis Market | Heart Pump Devices Market | Hydrocephalus Treatment Market | Impetigo Market | Indwelling Catheters Market | Intracranial Hemorrhage Market | Lambert-Eaton Myasthenic Syndrome Market | Lumbar Degenerative Disc Disease Market | Meibomian Gland Dysfunction Market | Metastatic Merkel Cell Carcinoma Market | Metastatic Prostate Cancer Market | Molluscum Contagiosum Market | Myopia Progression Market | NMOSD Market | Nocturia Market | Nonalcoholic Steatohepatitis Market | Nontuberculous Mycobacterial Infections Market
Other Reports by DelveInsight:
https://www.delveinsight.com/sample-request/late-stage-chronic-kidney-disease-ckd-pipeline-insight
https://www.delveinsight.com/sample-request/leiomyosarcoma-epidemiology-forecast
https://www.delveinsight.com/sample-request/leishmaniasis-pipeline-insight
https://www.delveinsight.com/sample-request/leukapheresis-market
https://www.delveinsight.com/sample-request/leukotriene-antagonist-pipeline-insight
https://www.delveinsight.com/sample-request/lice-infestations-market
https://www.delveinsight.com/sample-request/lipodystrophy-syndrome-ls-market-2027
https://www.delveinsight.com/sample-request/liq-861-drug-insight-and-market-forecast
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: abhishek@delveinsight.com
City: Albany
State: New York
Country: United States
